India, July 22 -- Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company developing radiopharmaceuticals for oncology, announced two key clinical updates today from its pipeline programs.
Positive Phase 2b Results for RAD101 in Brain Metastases Diagnosis
The company reported encouraging data from its Phase 2b trial of RAD101, a diagnostic imaging agent designed to detect brain metastases.
Brain metastases are a common complication in advanced cancers, often difficult to detect with conventional methods.
The study achieved its primary endpoint, with RAD101 demonstrating 86% accuracy in detecting brain metastases across multiple tumor types. The company noted that specificity data will be available in Q4 2026, pro...